IDC Perspective: How Technology Is Driving Diversity and Equity in Clinical Trials

IDC Perspective: How Technology Is Driving Diversity and Equity in Clinical Trials

This IDC Perspective reviews the existing landscape and critical challenges associated with driving diversity and equity in clinical trials. It reviews strategies that pharma is using to address these challenges and scans the evolving technology landscape that is playing a critical role in driving change. It also examines regulatory policies and guidances, identifies the key measures of success, and provides guidance on implementing a diversity strategy."Inclusive clinical development is a must to address the deep-rooted disparities that prevail across the globe. There is no silver bullet to address this issue. It requires a focused, sustained, and collaborative effort; it requires sensitivity and empathy to be woven into technology and strategy; and it calls for a genuine deep-seated commitment toward driving inclusiveness and equity in clinical trials," says Dr. Nimita Limaye, research vice president, Life Sciences R&D Strategy and Technology at IDC Health Insights.

Please Note: Extended description available upon request.


Executive Snapshot
Situation Overview
The Current Scenario
Where Do the Challenges Lie?
Evolving Regulations That Are Impacting D&I in Clinical Trials
Integrating Diversity into Approval Decisions for Oncology Studies
Strategies Leveraged by Pharma to Increase Diversity in Clinical Trials
Key Players Providing D&I Solutions
Identifying Measures of Success
Advice for the Technology Buyer
Learn More
Related Research
Synopsis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings